SDC3 (Syndecan 3)
Gene encoding a transmembrane heparan sulfate proteoglycan involved in cell signaling, adhesion, and lipid metabolism.
Gene Information Card
| Symbol | SDC3 |
|---|---|
| Full Name | Syndecan 3 |
| Gene Type | protein-coding |
| Chromosomal Location | 1p35.2 |
| NCBI Gene ID | 9672 ncbi.nlm.nih.gov/gene/9672 |
| Ensembl ID | ENSG00000162572 |
| UniProt ID | O75056 |
| OMIM ID | 600351 |
| HGNC ID | 10660 |
| Aliases | SYND3, N-syndecan, SDCN3 |
Description
SDC3 encodes syndecan 3, a transmembrane heparan sulfate proteoglycan that binds extracellular matrix components, growth factors, and cytokines. It plays roles in cell adhesion, migration, lipid metabolism, and neural development. SDC3 is implicated in obesity, insulin resistance, and certain cancers.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Obesity | SDC3 variants may alter lipid metabolism and energy balance, contributing to body weight regulation. | PMID: 14578974; GWAS catalog |
| Insulin resistance | Altered SDC3 expression affects insulin signaling and glucose uptake in adipose tissue. | PMID: 19381015 |
| Breast cancer | SDC3 overexpression promotes tumor cell proliferation and migration via heparan sulfate-mediated signaling. | PMID: 22952447; COSMIC |
| Colorectal cancer | SDC3 expression changes correlate with tumor stage and metastasis. | PMID: 25605247 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Adipose tissue | 8.2 | Low |
| Liver | 3.1 | Low |
| Kidney | 6.8 | Low |
| Lung | 4.5 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 15.3 | Embryonic kidney cells; high expression |
| MCF7 | 9.8 | Breast cancer cell line; moderate expression |
| HepG2 | 5.2 | Hepatocellular carcinoma; low expression |
| SH-SY5Y | 18.1 | Neuroblastoma; high expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.101C>T (p.Thr34Met) | Missense | <0.01% | Unknown; rare variant in population databases |
| c.457G>A (p.Gly153Ser) | Missense | <0.01% | Reported in ClinVar as uncertain significance |
| c.1234_1235insA | Frameshift | <0.01% | Predicted loss-of-function; not observed in healthy controls |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense variants predicted to truncate the protein, disrupting heparan sulfate attachment and signaling.
Gain of Function (GOF)
Not well characterized; overexpression in cancer may mimic gain-of-function effects.
Dominant Negative (DN)
No dominant-negative mutations reported for SDC3.
View complete mutation data：
Gene Ontology (GO)
| • heparan sulfate proteoglycan binding | • extracellular matrix binding |
| • growth factor binding | • cell adhesion |
| • signal transduction | • lipid metabolic process |
Pathways
• Heparan sulfate biosynthesis
• Syndecan-mediated signaling
• PI3K-Akt signaling pathway
• FGF signaling
Protein Summary
Syndecan 3 is a type I transmembrane protein with an extracellular domain bearing heparan sulfate chains. It interacts with ligands such as FGF, VEGF, and ECM components, modulating cell proliferation, migration, and lipid uptake. The protein is highly expressed in neural tissues and adipose tissue, and its dysregulation is linked to metabolic disorders and cancer progression.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SDC3 Knockout HEK293 Cell Line | EDJ-KQ3489 | Human | 9672 | Details Get a Quote |
| SDC3 Knockout A-549 Cell Line | EDJ-KQ25271 | Human | 9672 | Details Get a Quote |
| SDC3 Knockout HCT 116 Cell Line | EDJ-KQ25272 | Human | 9672 | Details Get a Quote |
| SDC3 Knockout HeLa Cell Line | EDJ-KQ25273 | Human | 9672 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
